J Korean Soc Emerg Med.  2001 Dec;12(4):565-569.

Rhabdomyolysis Associated with Cerivastatin-Gemfibrozil Combination Therapy: 1 case

• Kim SC
• Kim MC
• Ko YG

Abstract

Most currently available statins are associated with an increase with risk of myositis, including rhabdomyolysis. Myopathy is believed to be caused by interference in the cytochrome P450 3A4 enzyme system, which results in a marked increase in reductase activity. Cerivastatin, a new synthetic HMG-CoA reductase inhibitor, is a safe, well-tolerated effective drug for the treatment of patients with dyslipidemia. The drug is metabolized by the cytochrome P450 3A4 and cytochrome P450 2C8 hepatic isoenzymes. Because of this dual metabolic pathway, it has been suggested that cerivastatin is less subject to drug-todrug interactions. We describe a 60-year-old woman with rhabdomyolysis and localized myositis, after she had taken cerivastatin(lipobay, 0.3 mg/day) and gemfibrozil(lopid, 500 mg/day) for 1month.

Keyword

Cerivastatin; Gemfibrozil; Rhabdomyolysis

MeSH Terms

Cytochrome P-450 Enzyme System
Dyslipidemias
Female
Gemfibrozil
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Isoenzymes
Metabolic Networks and Pathways
Middle Aged
Muscular Diseases
Myositis
Oxidoreductases
Rhabdomyolysis*
Cytochrome P-450 Enzyme System
Gemfibrozil
Isoenzymes
Oxidoreductases